However, despite promising preclinical results, available data on HER2-targeted therapies in BTCs are controversial and are mainly limited to case reports and case series evaluating monoclonal antibodies in HER2-positive patients with metastatic disease [55,56]. The gene discussed is ERBB2; the disease is metastatic neoplasm.